Mektovi (Binimetinib)
- Medicine Name: Mektovi
- Generic Name: Binimetinib
- Dosage Form & Strength: Tablets: 15 mg
- Manufactured By: Array BioPharma Inc.
Medical Uses
Mektovi is a kinase inhibitor used, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
Recommended Dosage: The recommended dosage of Mektovi Tablet is 45 mg taken by mouth (orally) twice daily, approximately 12 hours apart, in combination with medicine encorafenib until the disease is progressive or unacceptable toxicity occurs.
Tablets may be taken with or without meals. Do not take a missed dose within 6 hours of the next dose of Mektovi.
Do not take any extra dose in case puking occurs after the administration of tablets but continue with the very next scheduled dose.
Note: Confirm the existence of a BRAF V600E or V600K mutation in tumor specimens prior to initiating Mektovi treatment.
Warning & Precautions
- Cardiomyopathy, manifesting as LVD (left ventricular dysfunction) associated with symptomatic or asymptomatic reductions in ejection fraction, may occur in those treated with mektovi 15 mg tablets in combination with drug encorafenib.
- Evaluate ejection fraction by echocardiogram or MUGA scan before initiating therapy, one month after starting therapy, and then every 2-3 months during therapy. Those with cardiovascular risk factors should be assessed precisely when treated with mektovi.
- Venous thromboembolism (VTE) may occur in those receiving Binimetinib along with encorafenib, including those who developed pulmonary embolism. Withhold, reduce dose, or permanently interrupt depending on severity of side effects.
- Serous retinopathy may occur in patients treated with binimetinib 15 mg tablets along with encorafenib. Evaluate for visual symptoms at each visit. Perform an ophthalmologic assessment on a regular basis, for new/worsening visual disturbances, and to follow new or persistent ophthalmologic findings.
- RVO is a known class-related side effect of MEK inhibitors and may occur in those treated with binimetinib along with encorafenib. Perform ophthalmologic examination for patient-reported acute vision loss or any other visual disturbance within 24 hours. Permanently discontinue drug in those with documented RVO.
- Uveitis, including iridocyclitis and iritis, may occur in those treated with binimetinib in combination with encorafenib. Visual symptoms should be assessed at each visit. Perform an ophthalmologic assessment at regular intervals.
- In those with BRAF mutation-positive melanoma receiving binimetinib tablets 15 mg along with encorafenib may develop interstitial lung disease (ILD), including pneumonitis. Assess new/progressive unexplained pulmonary signs and symptoms for possible ILD. Withhold, decrease dose, or permanently interrupt based on the severity of side effects.
- Hepatotoxicity may occur when binimetinib is administered along with encorafenib. Monitor liver laboratory tests prior to initiating therapy, monthly throughout the treatment. Withhold, decrease dose, or permanently interrupt based on severity of side effects.
- Rhabdomyolysis may occur when Mektovi is used in combination with drug encorafenib. Monitor CPK and creatinine levels before initiating mektovi tablets 15 mg, periodically throughout the treatment. Withhold, decrease dose, or permanently interrupt on behalf of severity of side effects.
- As per findings and its mechanism of action, Mektovi can cause fetal harm if administered to a pregnant woman. Females of reproductive age should use effective contraception throughout the treatment with and for at least 30 days after the last dose.
Documentation & Availability
What documents are required to import MEKTOVI to India?
MEKTOVI (Binimetinib) tablets can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patient’s diagnostic reports.
- Patient’s ID proof (issued by the Government of India).
How is the order confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from a doctor.
- Import permit if applicable.
Is MEKTOVI available in India?
MEKTOVI (binimetinib tablets) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
S S Healthcare (S S Healthcare) helps import cancer medicines on the named patient supply (NPS). S S Healthcare is facilitator providing input
- On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
MEKTOVI can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
S S Healthcare (S S Healthcare) can facilitate the supply of MEKTOVI (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).
Please contact +91-7575883015 | Number: +91-7575883015 or write us at sshealthcare1012@gmail.com for Mektovi tablets price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Sourcing & Delivery
S S Healthcare is able to source the MEKTOVI (Cancer Treatment Medicines) from across the globe, and has the ability to supply. S S Healthcare offers its customers worldwide access to the best available treatment.
S S Healthcare is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
FAQ
What is the Generic Name for the trade name drug Mektovi®?
Binimetinib is Generic Name for the trade name drug Mektovi®.
What is the Manufacturer Name of Mektovi®?
Mektovi® is manufactured by Array BioPharma Inc.
Is Mektovi® approved by the FDA?
Yes, Mektovi® is approved by the FDA. Date of first/initial approval: June 27, 2018.
Where can I get Mektovi® 15 mg at the best price in India?
To get the best mektovi 15 mg tablets price in India, contact S S Healthcare (WHO-GDP and ISO 9001 : 2008 authorized Company). A medical prescription is required while buying Mektovi®.
What is the dosage and form of Mektovi® supplied?
Mektovi® is supplied as Tablets: 15 mg for oral administration.
What are the most common side effects for Mektovi®?
The most common side effects for Mektovi along with medicine encorafenib, are fatigue, vomiting, nausea, diarrhea, and abdominal pain.
How much does Mektovi® cost in India?
The mektovi cost in India is less and can vary. In order to buy/procure this melanoma medication authentically, you can Call/WhatsApp +91-7575883015 or send mail to sshealthcare1012@gmail.com.
What are the storage conditions of Mektovi®?
Mektovi (binimetinib) is formulated as 15 mg yellow-dark yellow, oval film-coated tablets. Store tablets at 20-25°C (68-77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).
Is it safe to buy Mektovi® online from India?
Yes, You can buy mektovi tablets in India online at the best price from S S Healthcare if Mektovi® has not been approved or is not available in your country.
What are the Highlights of prescribing information for Mektovi®?
Click Here to download full Mektovi prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Email Address
Sshealthcare1012@gmail.com
+91 7575883015
Landline
079 48916267
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners, and S S Healthcare does not lay any claim on them. We only provide information.
